Superworth

Rallybio price to sales ratio RLYB

Market value divided by revenue over the last twelve months, since 2025.

Today, Oct 23, 2026
137×
Peer median
1.4×

Rallybio's price to sales ratio is 137× as of Oct 23, 2026.

The median for 10 large drugmakers of a similar size is 1.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far137×39.3×141×
202545.5×15.0×52.0×

Against its peers

Companies in Drug Manufacturers - General nearest Rallybio's size, closest first, today.

CompanyPrice to sales ratio
RLYBRallybio137×
LFVNLifevantage0.4×
SPROSpero Therapeutics1.4×
ATNMActinium Pharmaceuticalsn/m
NATRNatures Sunshine Products0.4×
ARVNArvinas1.5×
PBYIPuma Biotechnology2.5×
IRWDIronwood Pharmaceuticals1.5×
ZVRAZevra Therapeutics4.3×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical0.9×
Peer median1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Rallybio

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.